Cures 2.0 Mandatory Use Begins October 2, 2018

What is CURES?

The Controlled Substance Utilization Review and Evaluation System (CURES), maintained by the Department of Justice (DOJ), is a platform that tracks all Schedule II – IV controlled substances dispensed to patients in California. Authorized prescribers, pharmacists, law enforcement, and regulatory agencies can view information in CURES including:

  • patient name, date of birth, address
  • prescriber name, DEA number
  • pharmacy name, license number
  • date prescription was dispensed
  • prescription number
  • drug name, quantity and strength
  • number of refills remaining

For assistance with CURES 2.0 registration, access, or system use, contact the CURES helpdesk at or (916) 210-3187.

What are the Consequences for Failing to Consult CURES?

A health care practitioner who fails to consult the CURES database as required must be referred to their state professional licensing board for administrative sanctions, as deemed appropriate by that board.

CURES Registration at a Glance

Registration is done through DOJ’s CURES 2.0 Registration. Only licensed California prescribers and dispensers can register with CURES. (NOTE: If you are with a law enforcement agency or regulatory board and need CURES access, please contact the CURES helpdesk at or (916) 210-3187).

To register, licensed prescribers and dispensers will need:

  • A valid email address. This will be the exclusive email address to which CURES-related correspondence is sent.
  • Your state license information. This information will be verified with the regulatory board issuing your license.
  • Your federal DEA license information (prescribers only). This information will be verified with the Drug Enforcement Agency (DEA).

DOJ will process your registration application and send email notification of its approval or denial.

CURES Access

Once you receive DOJ email notification of your approved registration, you can access CURES 2.0 through DOJ’s CURES 2.0 Login. Reference the Prescriber and Dispenser User Guide for detailed information about navigating and using CURES 2.0.

Data Submission Requirements

Pharmacies and dispensing practitioners are required to report Schedule II-IV controlled substance prescription dispensing information on a weekly basis pursuant to California Health and Safety Code §§11165, 11190, 11164.1, and 11164.5, and Business and Professions Code §4068.

For data submission instructions or assistance with transmission issues, please contact:

Atlantic Associates, Inc. – CURES Prescription Data Collection Vendor

Toll Free: (800) 539-3370
Phone: (603) 627-7829
Fax: (877) 508-6704

CURES Upgrade: CURES 2.0

CURES Certification

On January 8, 2016, the DOJ released the CURES 2.0 system upgrade. This upgrade offers a significantly improved user experience and increased functionality:

  • Allow approved delegates to run patient report queries for access by prescribers and dispensers
  • Send peer-to-peer communications
  • Receive patient alerts

For More Information

To learn more about CURES 2.0, visit the following links:

You must be registered to use CURES, even if you do not actively prescribe or dispense, if you are a:

  • • California-licensed health care practitioner possessing a DEA number
  • • California-licensed pharmacist with an active license

(California Health & Safety Code § 11165.1)

Who is Required to Consult CURES?

Mandatory Use of CURES

Medical Board of California Mandatory Use FAQ

CURES 2.0 Webinar for Prescribers and Dispensers

Any health care practitioner authorized to prescribe, order, administer, or furnish a controlled substance, with limited exceptions, including:

  • • Physician and Surgeon
  • • Certified Nurse Midwife (Furnishing)
  • • Dentist
  • • Naturopathic Doctor
  • • Nurse Practitioner (Furnishing)
  • • Optometrist
  • • Physician Assistant
  • • Podiatrist

Note: This requirement does not apply to veterinarians or pharmacists.

New Legislation

AB 149 (Cooper) was signed into law on March 11, 2019, and takes effect immediately. This bill allows for a transition period, until January 1, 2021, before the new requirement becomes effective that prescription forms for controlled substances include a uniquely serialized number. This bill allows DOJ to extend this period for no longer than six additional months if the supply of compliant security prescription forms is inadequate. The purpose of this bill is to resolve the issues unintentionally created by AB 1753 (Low, Chapter 794, Statutes of 218).

AB 1753 (Low) was enacted to require an additional improvement to controlled substance security prescription forms: the addition of a unique serialized number to each form in a format approved by the Department of Justice. This change takes effect January 1, 2019.